Skip to main content

Prout Samantha's Form 4 filing

Amicus Therapeutics, Inc. (FOLD) · filed Aug 11, 2023

Accession no.
0001209191-23-045479
Filed
Aug 11, 2023
Trade date
Aug 9, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $517.1K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Prout SamanthaCIK 0001743122Officer (Chief Accounting Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 9, 2023Common StockMOption exerciseAcquired+2,376$10.04+$23,855.04139,379Direct
Aug 9, 2023Common StockMOption exerciseAcquired+5,040$9.55+$48,132144,419Direct
Aug 9, 2023Common StockMOption exerciseAcquired+10,592$10.03+$106,237.76155,011Direct
Aug 9, 2023Common StockMOption exerciseAcquired+18,901$12.11+$228,891.11173,912Direct
Aug 9, 2023Common StockSSaleDisposed−36,909$14.01F1−$517,095.09137,003Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 9, 2023Common StockMOption exerciseDisposed−2,376$0.00$00Direct
Aug 9, 2023Common StockMOption exerciseDisposed−5,040$0.00$02,526Direct
Aug 9, 2023Common StockMOption exerciseDisposed−10,592$0.00$03,176Direct
Aug 9, 2023Common StockMOption exerciseDisposed−18,901$0.00$037,810Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.00 to $14.10 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Remarks

All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2023.

Read the full filing on SEC EDGAR (opens in a new tab)